Patient-Based Therapeutics
AcuraStem is a near-to-clinic, patient-based, biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
Patient Focused
learn about our work
Neurodegenerative Disease Areas



Latest News
Sam Alworth, has been invited to present at Translational Solutions’ Virtual Investor...
The California ALS Research Summit held on Jan 24-25, 2020 was the tenth annual gathering of researchers, investigators, clinicians, biotech companies, government representatives, partner organizations, and advocates in ALS and related fields in the State of California. AcuraStem was proud to be on hand as mentor sponsors.
Nov 8-10, 2019, Shanghai, China: Co-Founders Sam Alworth and Dr. Qing Liu will be speaking on November 9th, 2019 at this prestigious summit for innovators on the "Future of Drug Discovery for CNS Indications."